TP53 and ovarian carcinoma: Indeed, combination of APR‐246 with the MRP1 inhibitor MK‐571 resulted in enhanced growth suppression in TP53 mutant TOV‐112D and OVCAR‐3 ovarian cancer cell lines and HCT116 colorectal cancer cells with WT or R248W mutant TP53 (Fig 1A), as well as several esophageal cancer cell lines (Fig EV1B) and cancer cell lines of other origins and different TP53 status (Appendix Fig S1A).